91 filings
Page 4 of 5
6-K
vn0ykya1
5 Feb 21
Index to Consolidated Financial Statements
4:21pm
6-K
7vsay vkng1
5 Feb 21
I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73
8:11am
6-K
jwqrtn75xhu1 ep
13 Nov 20
Current report (foreign)
4:02pm
6-K
29roorr1r5br1o3jxd6
12 Nov 20
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody
6:06am
6-K
jjw4aurp12
10 Nov 20
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
6:19am
6-K
w1ksy8e rc2fwmcz
5 Oct 20
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of
6:04am
6-K
y601h9os
22 Sep 20
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
6:05am
6-K
n4tc5
17 Sep 20
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
4:04pm
6-K
9kuwqw7r sx1p9
17 Sep 20
Current report (foreign)
4:01pm
6-K
cdi2 jpo4e
4 Sep 20
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
7:03am
6-K
d8x5qgah ewx35i3tja4
4 Sep 20
Current report (foreign)
7:02am
6-K
tp0bh23w299nimk4
1 Sep 20
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
6:10am
6-K
a663upxofpbzvaav
18 Aug 20
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
6:06am
6-K
47ytj2
5 Aug 20
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
6:07am
6-K
8lfpfs0tvx681
29 Jul 20
I-Mab Drives Commercialization Strategy with Appointment
6:13am
6-K
lifibxtj
15 Jul 20
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
4:51pm
6-K
qqp89d3r
15 Jun 20
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific
6:15am
6-K
1p3yrfqg
28 May 20
I-Mab Reports Interim Results from Part 1 Study forAnti-GM-CSF Antibody TJM2 to Treat
6:22am
6-K
wo8vidjg8ytdgvbs
21 May 20
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of
8:50am
6-K
mydptlrp
13 May 20
Current report (foreign)
4:01pm